Search

Aurinia Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

16.73 0.97

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.48

Max

16.8

Belangrijke statistieken

By Trading Economics

Inkomsten

3.1M

37M

Verkoop

5.5M

83M

K/W

Sectorgemiddelde

7.3

57.366

EPS

0.28

Winstmarge

44.958

Werknemers

128

EBITDA

4.8M

55M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.63% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

331M

2.2B

Vorige openingsprijs

15.76

Vorige sluitingsprijs

16.73

Nieuwssentiment

By Acuity

21%

79%

58 / 340 Rangschikking in Healthcare

Aurinia Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 aug 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 aug 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 aug 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 aug 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 aug 2026, 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 aug 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 aug 2026, 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 aug 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 aug 2026, 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 aug 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 aug 2026, 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 aug 2026, 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

6 aug 2026, 20:02 UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

4 aug 2026, 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

3 aug 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 aug 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 jul 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 jul 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 jul 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 jul 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 jul 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 jul 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 jul 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Peer Vergelijking

Prijswijziging

Aurinia Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

8.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  8.63%

Hoogste 21 USD

Laagste 16 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aurinia Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

58 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat